478 related articles for article (PubMed ID: 33274259)
1. Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.
Atabati E; Dehghani-Samani A; Mortazavimoghaddam SG
Can J Respir Ther; 2020; 56():1-9. PubMed ID: 33274259
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary hypertension in patients with interstitial lung diseases.
Ryu JH; Krowka MJ; Pellikka PA; Swanson KL; McGoon MD
Mayo Clin Proc; 2007 Mar; 82(3):342-50. PubMed ID: 17352370
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases.
Fukihara J; Kondoh Y
Respir Investig; 2023 Sep; 61(5):601-617. PubMed ID: 37429073
[TBL] [Abstract][Full Text] [Related]
4. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
5. Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases.
Ishiguro T; Kobayashi Y; Uozumi R; Takata N; Takaku Y; Kagiyama N; Kanauchi T; Shimizu Y; Takayanagi N
Intern Med; 2019; 58(24):3509-3519. PubMed ID: 31839671
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Hypertension in the Course of Interstitial Lung Diseases-A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy.
Kacprzak A; Tomkowski W; Szturmowicz M
Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510098
[TBL] [Abstract][Full Text] [Related]
7. Secondary Pulmonary Hypertension Among Patients Qualified for Lung Transplantation: Single-Center Study.
Stącel T; Urlik M; Nęcki M; Antończyk R; Latos M; Wajda-Pokrontka M; Tatoj Z; Zawadzki F; Przybyłowski P; Zembala M; Ochman M
Transplant Proc; 2020 Sep; 52(7):2101-2109. PubMed ID: 32336653
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients.
Giacomelli C; Piccarducci R; Marchetti L; Romei C; Martini C
Biochem Pharmacol; 2021 Nov; 193():114812. PubMed ID: 34687672
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases.
Saraya T; Kimura H; Kurai D; Tamura M; Ogawa Y; Mikura S; Sada M; Oda M; Watanabe T; Ohkuma K; Inoue M; Honda K; Watanabe M; Yokoyama T; Fujiwara M; Ishii H; Takizawa H
Respir Med; 2018 Mar; 136():88-92. PubMed ID: 29501253
[TBL] [Abstract][Full Text] [Related]
11. [Interstitial lung diseases among patients hospitalized in the Department of Respiratory Medicine in Radom District Hospital during the years 2000-2009].
Szafrański W
Pneumonol Alergol Pol; 2012; 80(6):523-32. PubMed ID: 23109204
[TBL] [Abstract][Full Text] [Related]
12. Viral infections in workers in hospital and research laboratory settings: a comparative review of infection modes and respective biosafety aspects.
Pedrosa PB; Cardoso TA
Int J Infect Dis; 2011 Jun; 15(6):e366-76. PubMed ID: 21497126
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W
ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316
[TBL] [Abstract][Full Text] [Related]
14. [Pulmonary fibrosis in patients with COVID-19: A review].
Chuchalin AG
Ter Arkh; 2022 Dec; 94(11):1333-1339. PubMed ID: 37167174
[TBL] [Abstract][Full Text] [Related]
15. Real-life prevalence of progressive fibrosing interstitial lung diseases.
Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
[TBL] [Abstract][Full Text] [Related]
16. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung diseases in dogs and cats part I: The idiopathic interstitial pneumonias.
Reinero C
Vet J; 2019 Jan; 243():48-54. PubMed ID: 30606439
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
[TBL] [Abstract][Full Text] [Related]
19. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary rehabilitation in interstitial lung diseases: A review of the literature.
Wytrychowski K; Hans-Wytrychowska A; Piesiak P; Majewska-Pulsakowska M; Rożek-Piechura K
Adv Clin Exp Med; 2020 Feb; 29(2):257-264. PubMed ID: 32101645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
